Dual agonist LY3298176 (tirzepatide) and triple agonists showed biased signaling toward ERK1/2 phosphorylation over cAMP at both GIP and GLP-1 receptors, which may influence clinical response diversity.
Biased agonismtirzepatide preferentially activates ERK1/2 over cAMP at both GIP and GLP-1 receptors
What the researchers found
LY3298176 (tirzepatide) is biased toward pERK1/2 relative to cAMP at both GIPR and GLP-1R. The triple agonist showed bias toward pERK1/2 relative to β-arrestin2 recruitment at GLP-1R. Mono-agonists Pro3GIP and Lys3GIP are biased toward pERK1/2 at GIPR.
Why it matters
Understanding biased agonism at gut hormone receptors explains why structurally similar drugs can have different clinical effects on weight loss, blood sugar, and side effects. This knowledge could guide design of next-generation obesity and diabetes drugs.
The numbers in context
Compared mono-, dual-, and tri-agonist profiles at GIPR, GLP-1R, and glucagon receptors.
How the study worked
Pharmacological characterization using HEK293 cells recombinantly expressing human GIPR or GLP-1R. Measured cAMP accumulation, ERK1/2 phosphorylation, and β-arrestin2 recruitment to determine signaling bias compared to endogenous ligands.
Who was studied
In vitro receptor binding and activation assays
What this study cannot tell us
HEK293 cell overexpression system may not fully replicate signaling in native tissues. Biased agonism observed in vitro may not directly predict clinical outcomes. The relationship between ERK1/2 bias and therapeutic efficacy needs clinical validation.
How to read the evidence
Rigorous in vitro pharmacological characterization with proper controls against endogenous ligands. Foundational receptor science but clinical significance of biased agonism needs further study.
When this study was published
Published in 2020, before tirzepatide (Mounjaro/Zepbound) received FDA approval. The biased agonism findings add pharmacological depth to understanding this blockbuster drug.
The bigger picture
The GLP-1 receptor agonist market has exploded with drugs like semaglutide and tirzepatide. This pharmacological deep-dive reveals that these drugs aren't simply 'turning on' receptors — they're activating them in nuanced ways that produce different downstream effects, potentially explaining the clinical superiority of dual agonists like tirzepatide.
Questions still open
- Does tirzepatide's ERK1/2 signaling bias explain its superior weight loss compared to GLP-1 mono-agonists?
- Can receptor signaling bias be engineered into next-generation dual/triple agonists for optimal clinical effects?
- How does biased agonism at gut hormone receptors affect gastrointestinal side effects?
Common questions
What is biased agonism?
What is LY3298176?
Read the original research
Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Biochemical pharmacology, 177, 114001
Citation
Yuliantie, Elita; Darbalaei, Sanaz; Dai, Antao; Zhao, Peishen; Yang, Dehua; Sexton, Patrick M; Wang, Ming-Wei; Wootten, Denise. (2020). Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.. Biochemical pharmacology, 177, 114001. https://doi.org/10.1016/j.bcp.2020.114001